Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry.
Christian VeltmannStefan WinterDavid DunckerCarsten G JungbauerNadine K WäßnigJ Christoph GellerJulia W ErathOlaf GoeingChristian PeringsMichael UlbrichMattias RoserDaniela HusserLaura S GanseraKorkut SoezenerFrank Michael MalurMichael BlockThomas FetschValentina KutyifaHelmut U KleinPublished in: Clinical research in cardiology : official journal of the German Cardiac Society (2020)
Mortality after WCD prescription was mainly driven by heart failure and non-cardiovascular death. In patients with HFrEF and a potential risk of sudden arrhythmic death, WCD protected observation of LVEF progression and appraisal of competing risks of potential non-arrhythmic death may enable improved selection for beneficial ICD implantation.